You just read:

CMX157 Demonstrates 99% Viral Load Reduction in Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread® in Hepatitis B Patients

News provided by

ContraVir Pharmaceuticals, Inc.

Oct 13, 2016, 06:00 ET